Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: diabetic nephropathies therapy - NephroGenex

Next Previous
X
Search
Drug Profile

Research programme: diabetic nephropathies therapy - NephroGenex

Alternative Names: BST 4946; BST 4996; BST 4997; BST-605

Latest Information Update: 12 May 2006

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BioStratum
  • Developer NephroGenex
  • Class Imidazoles; Piperazines; Pyridines
  • Mechanism of Action Advanced glycosylation end product inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Diabetic nephropathies

Most Recent Events

  • 12 May 2006 NephroGenex licenses second generation AGE compounds, including BST 605, from BioStratum
  • 17 Jun 2004 Data presented at the 64th Scientific Sessions of the American Diabetes Association (ADA-2004) have been added to the Diabetes pharmacodynamics section
  • 06 Apr 2004 This programme is available for licensing (http://www.biostratum.com)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top